Literature DB >> 16159882

A role for the distal carboxyl tails in generating the novel pharmacology and G protein activation profile of mu and delta opioid receptor hetero-oligomers.

Theresa Fan1, George Varghese, Tuan Nguyen, Roderick Tse, Brian F O'Dowd, Susan R George.   

Abstract

Opioid receptor pharmacology in vivo has predicted a greater number of receptor subtypes than explained by the profiles of the three cloned opioid receptors, and the functional dependence of the receptors on each other shown in gene-deleted animal models remains unexplained. One mechanism for such findings is the generation of novel signaling complexes by receptor hetero-oligomerization, which we previously showed results in significantly different pharmacology for mu and delta receptor hetero-oligomers compared with the individual receptors. In the present study, we show that deltorphin-II is a fully functional agonist of the mu-delta heteromer, which induced desensitization and inhibited adenylyl cyclase through a pertussis toxin-insensitive G protein. Activation of the mu-delta receptor heteromer resulted in preferential activation of Galpha(z), illustrated by incorporation of GTPgamma(35)S, whereas activation of the individually expressed mu and delta receptors preferentially activated Galpha(i). The unique pharmacology of the mu-delta heteromer was dependent on the reciprocal involvement of the distal carboxyl tails of both receptors, so that truncation of the distal mu receptor carboxyl tail modified the delta-selective ligand-binding pocket, and truncation of the delta receptor distal carboxyl tail modified the mu-selective binding pocket. The distal carboxyl tails of both receptors also had a significant role in receptor interaction, as evidenced by the reduced ability to co-immunoprecipitate when the carboxyl tails were truncated. The interaction between mu and delta receptors occurred constitutively when the receptors were co-expressed, but did not occur when receptor expression was temporally separated, indicating that the hetero-oligomers were generated by a co-translational mechanism.

Mesh:

Substances:

Year:  2005        PMID: 16159882     DOI: 10.1074/jbc.M505644200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

Review 1.  mRNA transcript diversity creates new opportunities for pharmacological intervention.

Authors:  Elizabeth S Barrie; Ryan M Smith; Jonathan C Sanford; Wolfgang Sadee
Journal:  Mol Pharmacol       Date:  2012-02-07       Impact factor: 4.436

Review 2.  Opioid receptor trafficking and signaling: what happens after opioid receptor activation?

Authors:  Jia-Ming Bian; Ning Wu; Rui-Bin Su; Jin Li
Journal:  Cell Mol Neurobiol       Date:  2011-09-25       Impact factor: 5.046

3.  Agonists at the δ-opioid receptor modify the binding of µ-receptor agonists to the µ-δ receptor hetero-oligomer.

Authors:  N Kabli; N Martin; T Fan; T Nguyen; A Hasbi; G Balboni; B F O'Dowd; S R George
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 4.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 5.  Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics.

Authors:  Subramaniam Ananthan
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

6.  Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers.

Authors:  Raphael Rozenfeld; Lakshmi A Devi
Journal:  FASEB J       Date:  2007-03-23       Impact factor: 5.191

Review 7.  A day in the life of a G protein-coupled receptor: the contribution to function of G protein-coupled receptor dimerization.

Authors:  G Milligan
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

8.  Computational study of the heterodimerization between mu and delta receptors.

Authors:  Xin Liu; Ming Kai; Lian Jin; Rui Wang
Journal:  J Comput Aided Mol Des       Date:  2009-02-13       Impact factor: 3.686

9.  Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors.

Authors:  Carla Ferrada; Estefanía Moreno; Vicent Casadó; Gerold Bongers; Antoni Cortés; Josefa Mallol; Enric I Canela; Rob Leurs; Sergi Ferré; Carme Lluís; Rafael Franco
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

10.  Direct interaction of GABAB receptors with M2 muscarinic receptors enhances muscarinic signaling.

Authors:  Stephanie B Boyer; Sinead M Clancy; Miho Terunuma; Raquel Revilla-Sanchez; Steven M Thomas; Stephen J Moss; Paul A Slesinger
Journal:  J Neurosci       Date:  2009-12-16       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.